Back to Top

Information For Authors

Health Equity Instructions for Authors

Health Equity is a peer-reviewed open access journal that addresses the urgent need for authoritative information about health disparities and health equity among vulnerable populations. Content ranges from translational research to prevention, diagnosis, treatment, and management of disease and illness toward the goal of optimal outcomes and ultimately health equity for all. Health Equity publishes open access to ensure broad and timely distribution of information without barriers to access.

Health Equity publishes original research, reviews, short reports, and perspectives in all of the areas identified above, as well as Letters to the Editor.

All manuscripts must be submitted through our online peer review submission systemPlease be sure to read through the Instructions for Authors prior to submitting your paper.

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

JOURNAL POLICIES

EXCLUSIVITY

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described as a footnote to the title.  By submitting a manuscript to Health Equity, the author(s) agree(s) to each of these conditions.

USE OF ENGLISH LANGUAGE

All submissions must be in English. Appropriate use of English is a requirement for review and publication in Health Equity. To support non-native speakers, Mary Ann Liebert, Inc., has partnered with Editage to provide language editing and translation services for a fee prior to official submission. To learn more about the services, please visit the Liebert Author Services website. Please note that employing the use of such services is not mandatory and using it, or any other language editing service, does not guarantee the acceptance of any paper. All submissions are subject to peer review.

INTERNAL REVIEW BOARD APPROVALS

All investigators who are engaged in research, regardless of funding, must comply with their institutions’ Internal Review Board procedures as well as federal regulations regarding the protection of human subjects.  Compliance must be indicated in the cover letter at the time of submission (see the Manuscript Preparation sections for cover letter requirements).  For further information, also see the Study Design and Ethics paragraph under the Publication Ethics and Malpractice Statement, below.

 

PEER REVIEW

Health Equity is a single-blind peer-reviewed journal.  All submissions to Health Equity are subject to peer review.  Authors are encouraged, but not required, to supply the names and valid email addresses of three to four individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be selected as a reviewer. However, reviewer selection is ultimately at the discretion of the Editor.

 

Use of English Language

All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Health Equity.  For authors whose native language is not English, we suggest using a service that can aid in the translation and rewriting of material into correct and proper English usage.  The Publisher offers this service, with a subsidy from the author, prior to official submission (Contact Editing@liebertpub.com for more information).  It is important to note that employing the use of the Publisher’s service, or any other editing service, does not guarantee acceptance of any paper.

Article Publication Charges (APCs)

Health Equity is an Open Access journal, with an Article Processing Charge (APC) of $950.00 USD. Mary Ann Liebert, Inc. will donate 5% of your APC fee to the charity of your choice from the following five charities:

  •   UNICEF
  •   National Medical Association
  •   The Humane Society International
  •   Nature Conservancy
  •  Doctors without Borders

PLAGIARISM DETECTION

Plagiarism: All submitted manuscripts will be processed through iThenticate, a plagiarism detection software. Plagiarized manuscripts will be rejected immediately.

 

ORCID ID

All authors are encouraged to complete their submissions using an ORCID identifier.  Please visit the ORCID website for more information, or to register.

 

Permissions and Reprints

Health Equity publishes articles under the Creative Commons Attribution license. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without requesting prior permission from the Publisher or the author.

 

Mary Ann Liebert, Inc., offers a reprint service for those who require professionally produced copies of a CC-BY licensed-article. Contact: Reprints@liebertpub.com to obtain a price quotation. Please include the article DOI, title, number of reprint copies, and delivery destination in your request.

 

Open Access and Copyright

All articles published in Health Equity are made freely and permanently accessible online upon publication without access or subscription charges, embargo periods, or user registration.

 

Upon submitting a manuscript for publication, the author(s) will agree to a Copyright and Open Access Licensing Agreement. Authors of articles published in the Journal will be the copyright holders and a Creative Commons CC BY license will be applied. For more information, please read the full Creative Commons CC BY license.

 

For authors who are US government employees or are prevented from being copyright holders for similar reasons, Liebert Open Access can accommodate non-standard copyright. Please contact: OpenAccess@liebertpub.com for more details.

 

Archiving and Preservation

Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Health Equity is fully NIH-, HHMI-, and Wellcome Trust-compliant.  Your article will be free online at www.liebertpub.com/heq, and will be easily searchable on Google, Google Scholar, and other search engines.

MANUSCRIPT PREPARATION

Please read all the instructions to authors before submitting.

Cover Letter
All submissions should include a cover letter from the corresponding author at the time of submission. The cover letter should include the following:

  • A declaration that the submission has received all authors’ Internal Review Board (IRB) approvals, if applicable.  If IRB approval has been waived, state the reason for exemption in the cover letter.
  • A statement detailing each listed author’s role to the development of the paper (see the Authorship paragraph* below for more information).
  • A statement indicating that the article has not been previously published in any form
  • A statement confirming that the article is not under consideration nor in press elsewhere
  • Authors are encouraged to detail the significance and uniqueness of the work in a single paragraph
  • If non-preferred reviewers are selected, please state the reason for exclusion.

 

AUTHORSHIP

Authorship* should be determined at the time of submission. Ensure the author listing is complete and all names are spelled correctly.  According to the International Committee of Medical Journal Editors (ICJME), authorship is based on the following criteria:

  1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  2. Drafting the work or revising it critically for important intellectual content; AND
  3. Final approval of the version to be published; AND
  4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
     

Corresponding Author:  It is the Journal’s policy that a submission carries only ONE corresponding author.  This designation should be determined at the time of submission.  All communications, except for individual copyright forms, will be managed through the corresponding author.

 

Acknowledgment of Non-Qualifying Contributors

Contributors who do not meet all four (4) of the above criteria for authorship should not be listed as authors, but they may be recognized in an Acknowledgment section. Some examples of activities that alone (without other contributions) do not qualify for authorship are: 

 

  • Acquisition of funding;
  • General supervision of a research group or general administrative support;
  • Writing assistance, technical editing, language editing, and proofreading.

Those whose contributions do not justify authorship may be acknowledged individually or together as a group under the heading, Acknowledgments, and should be included in at the end of the manuscript before the Author Disclosure Statement(s).

 

Submitting Author/Agent:  It is incumbent upon the submitting author/agent to ensure the inclusion and accuracy of all contributing authors’ names, valid email addresses, and affiliations upon original submission of the paper. Once a paper is accepted for publication, changes in authorship are generally not permitted.  Changes in authorship after publication are strictly prohibited.

 

WORD LIMITS

Article Type

Maximum Word Limit*

Abstract Word Limit

References

Figures

Tables

Original

3,000

250 (structured)

100

4

4

Review

4,000

400 (structured)

200

10

8

Narrative Review

4,000

300 (structured)

200

10

8

Short Reports

1,500

100 (structured)

25

3

3

Perspectives

1,500

100

25

3

3

Editorials

1,000

N/A

10

2

2

Letter to the Editor

500

N/A

5

1

1

*These limits relate to the text of the manuscript; word limits do NOT include the title, authors, affiliations, abstract, headings, figure and/or table legends, acknowledgments, disclosures, or references.

 

Submissions should not exceed the limits for text, figures/tables, and references listed in the table above.

 

*****Do not submit the manuscript or any of its components in PDF format.*****

 

ARTICLE TYPES

Original Articles:  Text must have an introduction and separate sections for Methods; Results; Discussion; and health equity implications.

 

Original Articles should include the following components:

  • Title page (see section labeled Title Page for requirements)
  • Structured Abstract: Purpose; Methods; Results; Conclusion (see word limit table above)
  • Text: Introduction; Methods; Results; Discussion; Conclusion; Acknowledgments, Disclosure(s)
  • References
  • Figure Legends

Review Articles (quantitative, narrative, and qualitative reviews):  The Journal recommends that you use the following headings to conform to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (title, abstract, methods, results, discussion, conclusion, acknowledgment, disclsoures/funding, references). For more information, visit the PRISMA website.

 Review Articles should include the following components:

  • Title page (see section labeled Title Page for requirements) 
  • Abstract (see word limit table above)
  • Text: Introduction; Methods; Results; Discussion; Conclusion, Acknowledgments, Disclosure(s). Details on the study selection and inclusion process and on the participants in each selected study should be included.
  • References.
  • Figure Legends

Narrative (non-systematic) Reviews

 

Narrative Reviews should address a clinical, educational, or methodological problem by combining expert opinions with a thorough and balanced review of available evidence. Narrative reviews are appropriate when the question of interest is too broad, the body of evidence too sparse, or the topic is too new or controversial for a systematic review. Structurally, authors should begin narrative reviews with an illustrative case or example. The review should put the topic into the context of the literature and interpret the evidence to resolve the problem for the reader.  Narrative Review articles should include the same components as a Review Article, detailed above.

Short Reports

Clinical reports, case series, particularly promising preliminary findings, or other research findings that are not suitable for a full Original Article.

 Short Reports should include the following components:

  • Title Page (see section labeled Title Page for requirements)
  • Abstract: Structured headings (Purpose; Methods; Results; Conclusion; see word limit table above).
  • Text
  • References
  • Figure Legends

Perspectives 

Perspectives present opinions and insights on a current topic, describe novel hypotheses, or consider controversial issues, including legal, policy, and ethical issues. These articles may provide critical commentary on recent advances and future directions and discuss implications for clinical practice or public health. The perspective and points in the article should be supported by relevant literature.

 Perspectives should include the following components: 

  • Title page
  • Abstract: Structured headings are not required.
  • Text: Introduction and a Conclusion are mandatory.
  • Figure Legends


Letters to the Editor

Letters should include the following components:

  • Title Page: Include a short title related to, but distinct from, the published article being addressed.
  • Text
  • References
  • Figure Legends

Special Note: The Editors may choose to invite the authors to submit a response to the Letter.

Keywords (Areas of Expertise)

To facilitate the peer review process, select 4-6 keywords from the drop-down list of pre-selected terms when submitting your manuscript.   These keywords will assist in the selection of skilled reviewers in the field for the purposes of peer review.

General Formatting and Style 

  • Font: Times New Roman or Arial in 12-point type
  • Abbreviations: Expand all abbreviations at first mention in the abstract, and then again text. Use abbreviations thereafter.
  • Page size: Letter size (8.5 x 11 inches)
  • Margins: 1 inch
  • Line and word spacing: Double-space all manuscript pages, including figure legends.

 

MANUSCRIPT COMPONENTS

FILE NAMING

  • Name figure files using only alphanumeric characters.  Do not use symbols, underscores, spaces, dots, or dashes.
  • File names must be in English.
  • For figures, file names should be formatted with first author’s last name and the figure number. (Ex:  SmithFig1)

Title Page

The title (first) page of all manuscripts should be part of the full manuscript file and must contain the following information:

  • Full title (No proprietary names, trade names, or abbreviations should be within the article title)
  • All participating authors should be listed on the manuscript at the time of submission (see Authorship* criteria above).  Changes in authorship are generally not permitted after acceptance of an article, and are not permissible after publication.
  • For each author, list:
    • Full name, including middle initial if applicable
    • Primary academic degrees (such as MD, DO, PhD, MPH, etc. No undergraduate or honorary degrees, fellowship or society memberships, etc.)
    • Institutional affiliation(s), including department, institution, city, and state
    • Valid email address

Co-first authors are permitted. On the title page, include an asterisk after each co-first author and include a corresponding footnote.

  • Running head: 50 characters or fewer (including spaces; abbreviations acceptable)
  • Word Count/Number of items: Indicate abstract and main text word counts and number of tables, figures, and appendices (if applicable).

ABSTRACT (must be included within the main article file, after the title page)

  • Do not use proprietary information, trade names, or references in the abstract.

MATERIAL AND METHODS SECTION

  • Must contain a statement about IRB approval, if applicable/required.

Acknowledgments
After the Conclusion of the main body of the manuscript, include a separate section acknowledging any contributors who did not meet the requirements for authorship and any science writers or corporate employees who participated in the development of the manuscript. Also include acknowledgments of research support for the study.

Author Disclosure Statement(s)

Following the Acknowledgments section (or Disclaimer if one was included), include a section entitled ‘‘Author Disclosure Statement.’’ Here authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will not influence the editorial decision. Please see the Uniform Requirements for Manuscripts Submitted to Biomedical Journals for further guidance. If no conflicts exist, the authors must state ‘‘No competing financial interests exist.’’

References
Authors are responsible for the accuracy and completeness of their references. Number references in the order they are cited in the text; do not alphabetize. In-text citations should be in sequential numerical order, superscripted, not contained within parentheses or brackets, and placed after punctuation.

 Begin the Reference section on a separate page after the Author Disclosure Statement section

  • Double-space all lines and single-space between words
  • Articles accepted and in press should be in the Reference section
  • Personal communications, unpublished data, or manuscripts “in preparation” or “submitted for publication” should not be included in the Reference section. If necessary, these should be included at the appropriate place, in parentheses, in the body of the text. Personal communications should include the contact’s first initial and last name, and the month and year of the communication.
  • List all authors and/or editors if there are up to 3; for 4 or more, list the first 3 followed by et al.
  • For books, volume and edition numbers should be included when appropriate
  • Abbreviate journal names in accordance with PubMed / MEDLINE
  • Do not include PMIDs or PCMIDs
  • References that are abstracts should be indicated as such, with the abstract number included, if applicable
  • Use DOI numbers only if the citation is from an online-only publication, or if final volume and/or pagination has not been assigned, or is not available.

Reference Samples

Journal Article

Punctuation and order of elements:

Last name First/middle initial, (up to 3 names, then et al.).Title of article (capitalize only first letter of title). Journal abbreviation as per PubMed. Year;volume #:full inclusive page range.

 

Sample:

Bailey JA, Willies-Jacobo LJ.  Are disadvantaged and underrepresented minority applicants more likely to apply to the program in medical education-health equity?  Acad Med. 2012;87:1535-1539.


Chapter in edited volume

Punctuation and order of elements:          

Last name First/Middle initial, (up to 3 names, then et al.). Title of chapter (capitalize only first letter of title).  In: Book Title (in italic; follow capitalization as it appears on the book cover).Edited by Last name First/Middle initials.  City of publisher: Name of publisher, year, pp. (inclusive page range).
Sample:
Thiede M, Akweongo P,  McIntyre D. Exploring the dimensions of access. In: The Economics of Health Equity. Edited by McIntyre D, Mooney G.  Canbridge: Cambridge University Press, 2007, pp. 103-123.


Book

Punctuation and order of elements:

Last name First/Middle initial(s).  Book Title (in italics; follow capitalization as it appears on the book cover).  City of publisher: Name of publisher, year.

Sample:

Takat A.  Health Equity, Social Justice, and Human Rights.  New York: Routledge, 2012.


Resolution by Professional Association
American Medical Association House of Delegates. Resolution 122 (A-08). 122. 2008.

Task Force Report    
American Psychological Association Task Force on Gender Identity and Gender Variance. Report of the Task Force on Gender Identity and Gender Variance.  2009. Washington, DC, American Psychological Association.

Publication by an Association
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision. DSM-IV-TR ed. Washington, DC, 2000.

 

Website

Centers for Disease Control and Prevention. HIV/AIDS among men who have sex with men. 2007. Available at www.cdc.gov/hiv/topics/msm/resources/factsheets/pdf/msm.pdf  Accessed June 12, 2015.

 

Tables
Within the text, cite tables in the order in which they appear using Arabic numerals. Tables in accepted articles will be typeset and placed near the first mention of the table in the text; do not include separate lines indicating table placement.

  • Prepare all tables in one separate Word file. 
  • Do not embed tables in the text where they are cited.
  • Provide a brief but descriptive title for each table.
  • Avoid abbreviations in the table title when possible.
  • Table footnote(s) should include any essential notes and must include definitions of all abbreviations and acronyms used in the table

Figures
Within the text, cite figures in the order in which they appear using Arabic numerals. Figures in accepted articles will be placed near the first mention of the figure in the text; do not include separate lines indicating figure placement.

  • Figures include graphs, charts, diagrams, illustrations, and photographic images
  • All figures must be submitted as separate files.  Do not embed figures within the main text file.
  • Do not prepare figures in Word.
  • Do not submit figures as PDFs, PowerPoint, or Excel files
  • Line illustrations should be submitted at a minimum of 600 DPI.  Halftones and color should be submitted at a minimum of 300 DPI
  • Color art should be saved as RGB.

Figure legends

After the Reference section of the article in the main Word document include a separate page with the following information for each figure:

  • A brief but descriptive title for each figure.
  • Avoid abbreviations in the figure title when possible
  • Define all relevant information in figures, including figure part labels, footnotes, abbreviations, acronyms, arrows, and levels of magnification in insets.

Appendix and supplementary material guidelines

  • Should be important to understanding or interpretation of the manuscript and limited in length
  • Should be original and not previously published
  • Acceptance of online-only materials is separate from acceptance of the manuscript and at the Editors’ discretion
  • Supplemental Information will not be copyedited or typeset; it will be posted online as supplied.)

MANUSCRIPT SUBMISSION

 Manuscripts must be submitted using the following URL:
http://mc.manuscriptcentral.com/heq

Create an Account in Manuscript Central

All authors on a submitted manuscript must have a Manuscript Central account for Health Equity.   If any listed author on a submission does not already have an account in Manuscript Central for the journal, one will need to be created. Once you create your account, you may log in to the system to begin your submission.

PUBLICATION ETHICS AND MALPRACTICE STATEMENT

Study Design and Ethics

Documented review and approval from a formally constituted review board (Institutional Review Board or Ethics committee) should be required for all studies involving people, medical records, and human tissues. For those investigators who do not have access to formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.

Animal experiments should require full compliance with local, national, ethical, and regulatory principles, and local licensing arrangements.

Definitions of Scientific Misconduct

Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  •  Authorship Disputes: Deliberate misrepresentation of a scientist’s contribution to the published work, or purposefully omitting the contributions of a scientist.
  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
  • Material failure to comply with legislative and regulatory requirements affecting research:
    Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
  • Conflict of Interest:  Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  • Plagiarism: Purposely claiming another’s work or idea as your own constitutes misconduct and/or fraud.
  • Simultaneous Submission:  Submitting a paper to more than one publication at the same time constitutes misconduct.

Responding to Allegations of Possible Misconduct

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation.  As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper.  In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record.  If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.

Protection of Research Participants

Informed Consent, Study Ethics Approval, and Subject Confidentiality

All manuscripts must comply with the recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals. For more information, visit The International Committee of Medical and Journal Editors.

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Helsinki Declaration as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.* In the Methods section of the article, authors must state that informed consent was obtained from subjects (specify written or verbal).

Patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, authors should provide assurance, and editors should so note, that such changes do not distort scientific meaning.*

 When reporting experiments on animals, authors should indicate whether institutional and national standards for the care and use of laboratory animals were followed.*

*These sections of Health Equity’s Instructions for Authors have been quoted directly from the International Committee of Medical Journal Editors website. For more information, visit www.icmje.org/recommendations/browse/roles-and-esponsibilities/protection-of-research-participants.html

Post-Submission Information

Submission-Related Emails and Online Status
The Manuscript Central system sends emails only to the corresponding author (except for copyright/licensing release emails for accepted articles).

Manuscript Decisions
Manuscripts may receive decisions of Reject, Major Revision, Minor Revision,  or Accept. A manuscript decision of Major Revision or Minor Revision does not guarantee the manuscript will ultimately be accepted. Article type word limits apply to revisions as well as initial submissions.

Permissions

Authors are responsible for procuring permissions to reproduce illustrations or tables taken from other publications and must be acknowledged by a complete credit line in the figure legend. The original publisher’s letter of permission should be available for submission to Health Equity if requested by the Editors and/or the Publisher. A full citation should also be included in the Reference section.

 

Page Proofs

An email containing a link to the PDF file of the page proof is sent to the corresponding author. The proof should be read carefully and returned within 3 business days to the Publisher with the author’s/authors’ approval or corrections.

 

Publisher

Health Equity is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215, Tel: (914) 740-2100; Fax: (914) 740-2101; Email: info@liebertpub.com;  Website: www.liebertpub.com/heq

 

Publisher Policies

All Mary Ann Liebert, Inc. journals follow the standards, guidelines, and best practices set forth by the -Committee on Publication Ethics (COPE; publicationethics.org), the International Committee of Journal Medical Editors (ICJME; www.icmje.org), the World Medical Association (WMA); www.wma.net) and the American Medical Association (www.ama-assn.org).

Health Equity is a single-blinded peer-reviewed journal. All submissions are subject to peer review. Upon submission, manuscripts are assessed by an editor for suitability for the journal.  For those that are deemed suitable, a minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Following peer review, the Editor and/or Associate Editors will determine if the paper should be accepted, require revision, or is unacceptable for publication.

Confidentiality in Peer Review

Editors and reviewers must maintain strict confidentiality of manuscripts during the peer-review process. Sharing a manuscript in whole or in part, outside the scope of what is necessary for assessment, is impermissible prior to an accepted manuscript's official publication date.

Sharing of Materials during Peer Review

Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review unless it violates the privacy or confidentiality of human research subjects.

Papers Authored by the Editor-in-Chief and/or Associate Editors

The Editor-in-Chief and Associate Editors will recuse themselves from participating in the review process of any manuscript in which there is a potential or actual competing interest.

Self-Citation and Self-Plagiarism

Health Equity is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works. (Deposition of a preprint on a preprint server is not considered as prior publication and will not impact consideration of any submitted manuscript.)

Time in Review

Health Equity aims to maintain a short, but thorough peer-review process. Depending on the length and complexity of the paper, the average time in review is 50+ days.  However, the Editor(s) will strive to expedite manuscript handling if/when special circumstances dictate.

ATTENTION:  To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.
 

AUTHORSHIP

Definition of Authorship

Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria:

  • Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
  • Drafting the work or revising it critically for important intellectual content; AND
  • Final approval of the version to be published; AND
  • Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Non-Author Contributors

Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged in the Acknowledgments section with a description of their contribution to the work.

For further information, visit the International Committee of Medical Journal Editors’ website at: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html

ORCID IDs

All submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

AUTHORSHIP LIMIT

There is a limit of 35 of authors permitted on a single submission, but in cases where there are 20 or more co-authors, Health Equity recommends that a collective group or consortium name be provided and the individual authors listed in the Acknowledgements.

CORRESPONDING AUTHOR**

One author should be designated as the corresponding author who will be responsible for communication between the authors and the journal editorial office(s) and publisher. This individual will be responsible for ensuring all authors submit copyright forms and coordinating and responding to page proofs, as well as any managing any other necessary contact during the peer review and/or production processes.

**NOTE: Due to configuration restraints, the submission system permits only one author to be identified as the corresponding author of record. However, we recognize that some submissions call for more than one corresponding author to be noted. In such cases, select one author to be the main point of contact and/or corresponding author for all communications regarding the peer review process of the paper, but on the title page of the manuscript, designate additional co-corresponding authors by including an asterisk after the authors' names in the byline, and include an accompanying footnote on the title page that reads, "*Co-corresponding authors."  Please ensure that the title page of the submission page carries the full affiliation details and email addresses of all authors who should be noted as a corresponding author. If the paper is accepted for publication, the full contact information for all desginated co-authors will be listed at the end of the article as per usual journal style.

WORKING GROUPS / TEAM AUTHORSHIP

Working Groups or Teams may be listed in the manuscript byline, but the entire listing of names and affiliations should be included in the acknowledgment section of the manuscript. Do not list the names in a footnote on the title page.

VARIATIONS OF AUTHORSHIP

It is permissible to list up to three authors as co-first authors, or as contributing equally to the work. Include an asterisk (*) next to the authors' names who are considered as first authors. Include a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors."

CHANGES IN AUTHORSHIP

Changes in authorship after submission or acceptance of a paper are strongly discouraged, but the editorial leadership recognizes that in certain circumstances, it may be required. The journal's policy for such cases is as follows:

  • A request to alter authorship must be made in writing from the corresponding author to the Editor-in-Chief, with a detailed explanation for the request, and the names and affiliations of the authors requiring addition and/or deletion.
  • Authorship may be altered after submission or acceptance of a paper ONLY with the expressed written approval of all authors named on the manuscript, as well as the individual(s) being added and/or deleted. The Publisher can provide a form for this, if needed.
  • Upon receipt of the request and all written approvals of all involved parties, the Editor-in-Chief will consider the request, render a decision, and notify the corresponding author.
  • There is a one-year post-publication statute of limitation on requests for alterations in authorship.
  • Post-publication changes or alterations to conference abstracts are prohibited.

ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

EXCLUSIVITY

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of a conference abstract.  If work was presented at a conference, supply the name, date, and location of the meeting as a footnote on the title page of the submission.

AUTHOR DISCLOSURE STATEMENTS

  • Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
  • Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
  • Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
  • Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
  • Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

SELF-CITATION AND SELF-PLAGIARISM

Health Equity is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

AFFILIATIONS

Authors should identify as their institution(s) the facility where the work was performed and executed.  Changes in an author’s affiliation after the work was completed but prior to the submission or publication of the manuscript should be noted by including an asterisk as a superscript to the name in the author listing, as well as a corresponding footnote on the title page indicating “Current Address” listing the new affiliation.   Corrections to affiliations or contact information due to relocation after publication is not permitted.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

INTERNAL REVIEW BOARD APPROVALS/WAIVERS

(as described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.

ETHICS OF EXPERIMENTATION

All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (http://ethics.od.nih.gov/).

ETHICAL TREATMENT OF ANIMALS

All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.

For further information, consult the World Medical Association’s website: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

AUTHOR DISCLOSURE STATEMENTS

  • Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
  • Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
  • Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
  • Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
  • Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

INTERNAL REVIEW BOARD APPROVALS/WAIVERS

(as described and defined on the World Medical Association's website; www.wma.net)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.

If the study is judged exempt from review, a statement from the committee is required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included in the Materials and Methods section of the manuscript.

ARTICLE PROCESSING CHARGES (APCs)

  • Health Equity is an Open Access journal, with an Article Processing Charge (APC) of $950.00 USD.
  • There are no charges for publishing images in color in Health Equity.
  • For pricing and purchasing reprints, contact our Reprints Manager.

    Any fees collected or payments associated with a submitted and/or published paper that is subsequently withdrawn and/or retracted for any reason are non-refundable.

Author(s) will be granted a Creative Commons CC-BY license and the article will be published as Open Access. If, for some reason, individual authors or groups of authors cannot personally accept the CC-BY license, it can be assigned to an institution, organization, or government.  This should be noted at the page proofs stage.

PERMISSIONS

When reproducing copyrighted material in a manuscript such as figures, tables, or excerpted text, the author(s) of the submitted paper must obtain permission from the original publisher and submit it concurrently with the manuscript. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al." and list the appropriate reference. All permissions must be supplied at the time of submission.  Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.

REUSE OF MATERIAL POSTED ON SOCIAL MEDIA

As material posted on social media platforms is usually not peer-reviewed content, it is not permitted as an official citation and/or reference.

Mary Ann Liebert, Inc., publishers permits the use of accepted pre-published manuscripts for the sole purpose of pitching to news organizations under strict embargo, and with the approval of and expressed collaboration with the publisher. A watermarked PDF version of the article (not a Word document or any other editable version) may be shared only with named, personal contacts at trusted news sources upon request. News sources must be informed upon delivery of the PDF that the manuscript is for reference-only purposes and can be used only in preparation of their news coverage of the article. It is strictly prohibited to publicly share, post, or otherwise distribute the PDF in any media format. Upon official publication of the article, news organizations must link directly to the published article on the publisher’s journal website. To coordinate publication timing and press efforts, please contact the Director of Marketing, Kathryn Ryan (kryan@liebertpub.com).

DATA SHARING

Health Equity strongly advocates the sharing and archiving of the data and any other artifacts that define and support the results stated in a manuscript in a suitable public repository (in accordance with valid privacy, legal, and ethical guidelines). A data availability statement should be included in the manuscript (in the Methods section or as a separate section at the end of the manuscript), describing the location of the data, with details on how it can be accessed as well as any licensing information. If the data is not publicly available or accessible, that information should also be provided.

Datasets should be cited in the reference list by Author (Year). Title. Publisher. Identifier/DOI.

Important: Please check with your funding agencies to ensure that are you following their data sharing polices. If your funding agency has additional requirements exceeding our policy, you must follow the requirements of your funder.

PREPRINT SERVERS

A preprint is a complete draft of a research paper that is shared on a public preprint server prior to submission to a journal for peer review.
 
Mary Ann Liebert, Inc., allows for papers that were previously deposited on preprint servers to be submitted to our journals, with the proviso that the author updates any preprint versions with a link to the final published article.  All submissions are subject to peer review and allowing the submission of preprint manuscripts does not guarantee publication in any Mary Ann Liebert, Inc., journal.
 
The submitting author of a paper that was previously deposited to a preprint server should include a disclosure on the title page of the manuscript indicating the name and website of the server and include the DOI number of the preprint.
 
Referencing/citing non-peer-reviewed material that is found on any preprint server is generally discouraged by Mary Ann Liebert, Inc., journals, but if it is necessary, the citation must make it clear that the content is not officially published in a journal, and can only be found on a preprint server.

 

RESEARCH FUNDER COMPLIANCE (FundRef)

Upon submission of a manuscript, the submitting agent will have an opportunity to enter funding/grant information. If funding information is entered correctly, the publisher will deposit the funding acknowledgements from the article as part of the standard metadata to FundRef. The entered information should include funder names, funder IDs (if available), and associated grant numbers.  Special care should be taken when entering this information to ensure total accuracy. (See https://www.crossref.org/services/funder-registry/ for a listing of more than 13,000 international funding agencies.)

GOVERNMENT FUNDED RESEARCH

Health Equity is fully NIH-, HHMI-, RCUK, and Wellcome Trust-compliant.

OPEN ACCESS

Our open access publishing solutions allow you to comply with the open access policies of your institution, government, and funding body. If you are employed or funded by the National Institute of Health (NIH), the Wellcome Trust, Research Councils UK (RCUK), or Howard Hughes Medical Institute (HHMI), you can find more information below:

  • NIH and HHMI Public Access Policy–In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final paginated version of the published article to PubMed Central (PMC) on behalf of the authors after a 12-month embargo period. Authors need not take any action. This service is provided free of charge. Authors who wish to remove the 12-month embargo period are encouraged to consider publishing with Open Option.
  • Wellcome Trust Policy–To easily comply, you can choose to have your article published open access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the Wellcome Trust.
  • Research Councils UK (RCUK)–To easily comply, you can choose to have your article published Open Access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the RCUK.

ATTENTION: To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

  • manuscriptcentral.com
  • amazonses.com
  • liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

POST-ACCEPTANCE / PRODUCTION

All accepted manuscripts will go through copyediting, typesetting, figure sizing and placement, author proofing, corrections, revisions (from corrected proofs), online-ahead-of-print release, and lastly, issue assignment. Depending on the length and complexity of any accepted submission, these steps typically take 3-6 weeks from acceptance.  Changes or alterations to a submission are not permitted after acceptance, but should be addressed in page proofs.

PAGE PROOFS

Page proofs will be sent to the corresponding author as designated in Manuscript Central when the manuscript was submitted. It is the corresponding author's responsibility to share the page proofs with co-authors, if desired, and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors/sources.

AUTHOR RESPONSE TO GALLEY PROOF

  • The corresponding author is responsible for returning corrected galley proofs generally within 72 hours of receipt.
  • If the corresponding author does not respond within that timeframe, the manuscript may be delayed in the publication schedule, or published as is, at the discretion of the Editor and Publisher.
  • If the corresponding author expects to be unavailable during the time the manuscript is in production, the publisher should be provided with an alternate contact. 
  • Only corrections directly related to errors in typesetting and/or layout will be allowed.
  • Any requested changes related to content, or that alter the outcome of a study, will require the approval of the Editor, and may require further peer review.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.

POST-PUBLICATION CORRECTIONS

In the event an error is discovered after publication of an article, the corresponding author should submit the correction in writing to the editorial office for consideration.  After editor approval, alterations will be made to the online version of the article, and if the errors are significant, an official correction statement will be issued.

  • Changes to author affiliations or contact details due to relocation after publication are not permitted.
  • Corrections to meeting abstracts will be made only to the online version.  The Journal does not issue formal correction statements for corrections to meeting abstracts, regardless of the nature of the correction.
  • Correction Statements/Errata to published articles that require the reproduction of color figure(s) and/or table(s) may incur additional costs to the author(s).

RETRACTIONS**

The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction.

**Any publication fees for retracted and/or withdrawn articles are nonrefundable in any circumstance.

STUDY DESIGN AND ETHICS

RESPONDING TO ALLEGATIONS OF POSSIBLE MISCONDUCT

The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.

When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.

Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.

If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.

All allegations will be kept confidential.

DEFINITIONS OF SCIENTIFIC MISCONDUCT

Mary Ann Liebert, Inc., publishers follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

  • Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
  • Authorship Disputes: Deliberate misrepresentation of a scientist's contribution to the published work, or purposefully omitting the contributions of a scientist.
  • Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
  • Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
  • Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
  • Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
  • Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
  • Plagiarism: Purposely claiming another's work or idea as your own constitutes misconduct and/or fraud.
  • Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.

RETRACTIONS

The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice explaining in full detail the circumstances surrounding the need for a retraction.

Three versions of the article format versions are referenced in the below policy guidelines:

•    Original Submission: The article version that is submitted by the author for consideration, before peer review.
•    Accepted Version: The article version that has been formally accepted after peer review, prior to any typesetting for the journal. This is the version accepted by the editor, before proofs, corrections, and typesetting. Also known as the “raw” accepted version of a manuscript.
•    Article of Record: This article version is the “version of record” that has been formally copyedited, typeset, and published online epub ahead of print and/or in a journal issue. It is the same version published in the “Online Now” section of the journal website.

Self-Archiving Policy

Mary Ann Liebert, Inc., publishers offers authors many options and opportunities to self-archive their work. Self-archiving of work is also referred to, or known as, publishing “Green Open Access”.

Authors can self-archive the original submission version of their article on any website or repository without embargo.

Additionally, authors can self-archive the accepted version of their article on their personal websites or institutional repositories only, without embargo. Any archiving of the accepted version for inclusion in subject-based repositories, such as PubMed Central (PMC), should follow the requirements of the funder of the work.  

Authors are not allowed to publish or self-archive the article of record on any website, social media platform, or repository without permission from Mary Ann Liebert, Inc., publishers, unless they publish their paper Gold Open Access (OA). Learn more about publishing your work Open Access here.

Mary Ann Liebert, Inc., publishers’ society partners or associated affiliates may set self-archiving policies independently, outside of the below -mentioned general policies. Authors should refer to the copyright policy of their chosen journal, which can be found on the Journal Collection Page or by contacting the specific journal editorial office directly. In addition, specific funding organizations have separate agreements and authors should refer to the policies of those specific funding agencies prior to the submission of their manuscript.

Original Submission Version

The original submission version of an article is the author's version that has not been peer reviewed.

This version may be placed on:

•    The author's personal website
•    The author's company or institutional repository or archive
•    Any not-for-profit subject-based preprint servers or repositories

Self-archiving of the original submission version is not subject to an embargo period.

If your submission is formally accepted after peer review in one of our journals, authors must include an acknowledgement of acceptance for publication on all archive sites and, following online publication, authors must include the following notice on the first page:

This is the original submission version (pre-peer review) of the following article: [full citation], which has now been formally published in final form at Health Equity at [link to final article using the DOI]. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

The original submission version posted may never be updated or replaced with the article of record version unless the author chooses to publish their paper OA under any of the Creative Commons Licenses available through the publisher. If you are interested in publishing your work OA, please feel free to review our Open Access policies and Licenses or contact us.

Accepted Version

Authors may only archive the accepted version of their manuscript on their personal and professional websites, and/or the author’s institutional repository or archive. Any archiving of the accepted version for inclusion in subject-based repositories, such as PubMed Central (PMC), should follow the requirements of the funder of the work. This process may impose additional embargo periods.  

The accepted version may be placed on:
•    The author's personal website
•    The author's company/institutional repository or archive

The accepted version posted must include the following notice on the first page:

This is the accepted version of the following article: [full citation], which has now been formally published in final form at Health Equity at [link to final article using the DOI]. This original submission version of the article may be used for non-commercial purposes in accordance with the Mary Ann Liebert, Inc., publishers’ self-archiving terms and conditions.

The posted accepted version may never be updated or replaced with the article of record version unless the author chooses to publish their paper Open Access under any of the Creative Commons Licenses available through the publisher. If you are interested in publishing your work OA, please feel free to review our Open Access policies and Licenses or contact us.

Article of Record

The article of record version may never be archived on a website, or in a repository or research network, unless published Gold Open Access under any of the Creative Commons Licenses available through the publisher. If you have questions, please contact us for more information. You can also review our Open Access policies and Licenses.

Funder Requirements

Mary Ann Liebert, Inc. publishers adheres to national and international funder requirements. Various funders, such as the National Institutes of Health (NIH), Wellcome Trust, Howard Hughes Medical Institute (HHMI), The Bill & Melinda Gates Foundation, and UK Research and Innovation (UKRI), for example, have specific requirements for depositing the accepted version and/or the article of record version of the author manuscript in a repository after an embargo period. Authors funded by these organizations should follow the self-archiving terms and conditions of these separate agreements based on the policies of the specific funding institutions. If you have questions, please contact us for more information.

Terms and Conditions for Use of All Self-Archived Article Versions

Authors may use either the original submission version or accepted version in the following ways:

•    For purposes of your own curriculum or teaching, dissertation, thesis, or book provided that all posted versions include the aforementioned notices, and follow all guidelines and requirements specified.
•    To share with researchers and research colleagues provided that such sharing is not for commercial purposes.

The self-archived submitted and accepted versions may only be used in non-commercial capacities. Individual users may view, print, download, and copy self-archived articles, as well as text and data mine the content conditions for non-commercial and non-promotional research and private study purposes, under the following requirements:

•    The authors' moral rights are not compromised and there is clear "attribution" of the author(s) in the shared work.
•    The authors’ integrity remains intact; the work should never be altered in such a way that the author's reputation or integrity may be damaged.
•    Any reuse complies with the copyright policies of the owner of that content.
•    Self-archived content may never be republished verbatim in whole or in part in print or online formats.

 

 

The Office of Foreign Assets Control (OFAC) of the US Department of the Treasury administers and enforces economic and trade sanctions based on US foreign policy and national security goals against targeted foreign countries and regimes, terrorists, international narcotics traffickers, those engaged in activities related to the proliferation of weapons of mass destruction, and other threats to the national security, foreign policy or economy of the United States. (Source: https://www.treasury.gov/about/organizational-structure/offices/pages/office-of-foreign-assets-control.aspx)

Our journal editors welcome contributions from researchers around the world; however, they are also required to follow sanction laws and regulations. Upon the date of this update (August 2020), sanction measures imposed by the United States, United Nations, European Union, and Australia are currently in place against the following countries: Cuba, Crimea, Iran, North Korea, and Syria. Journal editors will treat with caution any submission from a sanctioned country regarding the subject matter and will seek appropriate legal advice from the publisher if necessary.

Papers from sanctioned countries that are submitted to any Mary Ann Liebert, Inc., journal MUST contain a confirmation statement after the conclusion section of the manuscript which indicates that EACH listed author confirms that their research is supported by an institution that is primarily involved in education or research.

For further questions, please contact our Director of Production and Editorial Operations.

ARCHIVING AND PRESERVATION

Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Your article will be easily searchable on Google, Google Scholar, and other search engines.

PUBLISHER

Health Equity is owned and published by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801; Tel: 914-740-2100; Email: Info@liebertpub.com; Website: www.liebertpub.com/HEQ

Health Equity is a journal of broad interest that has been launched to overcome unnecessary barriers to the immediate availability and use of research.

Benefits of publishing in Health Equity:

  • High visibility, immediate and unrestricted online access to published articles
  • Rigorous peer review
  • Easy compliance with open access mandates
  • Authors retain copyright 
  • Highly indexed – citation tracking and inclusion in bibliographic databases
  • Targeted email marketing

Copyright and Licensing
Health Equity publishes articles under the liberal CC-BY license. This means that articles can be freely redistributed and reused by the author and others as long as the article is properly cited. Published articles in Health Equity can be deposited immediately into an online repository or social network without an embargo. Health Equity articles can be emailed to colleagues, printed, archived in a collection, included in course-packs, and distributed without restrictions. Please read the full Creative Commons license for further information.

JOURNAL FEES

  • Health Equity is an Open Access journal, with an Article Processing Charge (APC) of $950.00 USD.
  • There are no charges for publishing images in color in Health Equity.
  • For pricing and purchasing reprints, contact our Reprints Manager.
  • Any fees collected or payments associated with a submitted and/or published paper that is subsequently withdrawn and/or retracted for any reason are non-refundable.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.